Semi-Preparative Affinity Column
Tosoh Bioscience introduced the TSKgel FcR-IIIA-5PW HPLC column, a semi-preparative affinity column based on a recombinant FcγRIIIA receptor ligand bonded to porous 10 µm polymethacrylate particles.
Tosoh Bioscience introduced the TSKgel FcR-IIIA-5PW HPLC column, a semi-preparative affinity column based on a recombinant FcγRIIIA receptor ligand bonded to porous 10 µm polymethacrylate particles. The column is the newest addition to the company’s FcRγ affinity chromatography portfolio for antibody drug analysis. With the ability to be loaded with up to 5 mg of monoclonal antibody (mAb), the column allows for an adequate amount of material collection for thorough analysis.
Along with the FcR-IIIA-NPR, a separate column in Tosoh’s FcRγ affinity chromatography portfolio, the column separates antibodies according to the affinity of their Fc region for a particular Fc receptor (FcγIIIa) into three fractions, which correspond with different mAb glycoforms and their antibody-dependent cellular cytotoxicity activity. The columns represent a tool that link the FcγIIIa receptor affinity with mAb function and structure. Additionally, characterizing each fraction with orthogonal methods connects FcγIIIa receptor affinity to structural causes and functional effects.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
